MEI PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.105 USD | -1.74% |
|
-1.74% | -46.47% |
Presentation Operator MessageOperator (Operator)Good afternoon and welcome to the MEI Pharma 2...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. Its drug candidate pipeline includes Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib is a potent and selective orally administered CDK9 inhibitor. Voruciclib is being studied in a Phase 1 trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) and B-cell malignancies as a single-agent, and in combination with the B-cell lymphoma 2 (BCL) inhibitor venetoclax (marketed as Venclexta) in patients with AML. ME-344 is a novel mitochondrial inhibitor drug candidate that demonstrates tumor selective activity in pre-clinical studies. It targets the OXPHOS pathway involved in the production of adenosine triphosphate (ATP).
Calendar
2024-08-28
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
3.16
USD
Average target price
22.67
USD
Spread / Average Target
+617.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.47% | 21.05M | |
| +29.77% | 49.18B | |
| +1.00% | 42.11B | |
| +50.47% | 40.37B | |
| -5.26% | 28.85B | |
| +13.68% | 26.09B | |
| -22.99% | 18.71B | |
| +8.22% | 13.26B | |
| +32.41% | 12.32B | |
| -1.62% | 11.99B |
- Stock Market
- Equities
- MEIP Stock
- News MEI Pharma, Inc.
- Transcript : MEI Pharma, Inc., 2019 Earnings Call, Aug 28, 2019